TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03893045
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
Study: NCT03625531
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
Study: NCT03625531
Drug: Placebo letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
Study: NCT01767584
Drug: Cephalexin 1g tablets
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product
Study: NCT01767584
Drug: Cephalexin 1g tablets
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product
Study: NCT01271140
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
Study: NCT00544934
Drug: GLY-230
Normalized name: Gly
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125, 250 0r 375 mg bid for 14 days
Study: NCT01059383
Drug: Esomeprazole 20 mg
Normalized name: esomeprazole 20 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule, orally, once daily 30-60 min. before dinner
Study: NCT02673229
Drug: Collagenase Santyl
Normalized name: collagenase Topical Ointment [Santyl]
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
Study: NCT02673229
Drug: Bacitracin
Normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
Study: NCT00499109
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GD Group: 40 mg/m\^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m\^2 on day 1~DV Group: 50 mg/m\^2 on days 1 and 15, every 28 days
Study: NCT00499109
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DV Group: 35 mg/m\^2 on days 1 and 15
Study: NCT00499109
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.
Study: NCT00499109
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.
Study: NCT01943552
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium bromide
Study: NCT00003719
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00084149
Drug: Abacavir sulfate, Lamivudine, and Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antiretroviral therapy
Study: NCT00084149
Drug: Lopinavir/Ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: antiretroviral therapy
Study: NCT04477057
Drug: HS-10241
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10241 is a tablet in the form of 100 mg, oral, once daily.
Study: NCT04274803
Drug: Conventional therapy of antiphospholipis syndrome
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
Study: NCT03230292
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Bimekizumab will be administered subcutaneously in 2 different doses.
Study: NCT03118830
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
Study: NCT03118830
Drug: cetrorelix
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
Study: NCT04302064
Drug: Eplontersen
Normalized name: EPLONTERSEN
DrugBank: Eplontersen (DB16199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplontersen administered SC
Study: NCT00830193
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
Study: NCT01475162
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
Study: NCT03752723
Drug: GX-I7
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m.
Study: NCT03752723
Drug: Pembrolizumab(KEYTRUDA®)
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: i.v.
Study: NCT00117689
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Between Day 3 the last dose of Thymoglobulin
Study: NCT00117689
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: for at least 1 month posttransplant
Study: NCT02282904
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).
Study: NCT02282904
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 over 30 minutes Day -6 through Day -2
Study: NCT02282904
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
Study: NCT00560495
Drug: ammonium tetrathiomolybdate
Normalized name: Ammonium tetrathiomolybdate
DrugBank: Ammonium tetrathiomolybdate (DB17641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 times daily for up to 3 weeks
Study: NCT00442325
Drug: Atorvastatin (Lipitor)
Normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04242056
Drug: 18F-PM-PBB3
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets.
Study: NCT02896270
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
Study: NCT00514020
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 ml D5W through a vein over 2 hours on days 1 and 15.
Study: NCT01092962
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200mg/m²/jour in two divided doses during 18 months
Study: NCT04560894
Drug: SCT-I10A
Normalized name: Immunoglobulin g4 (226-proline), anti-(human programmed cell death 1) (human-mus musculus monoclonal sct-i10a .gamma.4-chain), disulfide with human-mus musculus monoclonal sct-i10a .kappa.-chain, dimer
DrugBank: Finotonlimab (DB18859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive SCT-I10A intravenously，200mg，d1，Q3w
Study: NCT04560894
Drug: Sorafenib 200mg
Normalized name: SORAFENIB 200MG TAB
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive sorafenib orally，400mg bid
Study: NCT02418104
Drug: CHS-1701
Normalized name: CHS-828
DrugBank: CHS-828 (DB12980)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02418104
Drug: Pegfilgrastim (Neulasta)
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04705948
Drug: Magnesium sulfate versus ketamine
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
Study: NCT04334564
Drug: Ginkgo biloba capsule
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
Study: NCT00828789
Drug: Efavirenz; Tenofovir disoproxil fumarate; Telaprevir
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02678884
Drug: 18-F FDG
Normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
Study: NCT04639817
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin administration
Study: NCT04639817
Drug: trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole administration
Study: NCT03283436
Drug: Bupivacaine Hydrochloride 0.25% Injection Solution
Normalized name: Bupivacaine Hydrochloride 0.25% Injection Solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
Study: NCT02049138
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet taken orally
Study: NCT00148785
Drug: Indinavir/Ritonavir/Fosamprenavir
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00363831
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m² infusion day 1, repeat every 21 days
Study: NCT02415790
Drug: E2027
Normalized name: Elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
Study: NCT00863551
Drug: Trospium Chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release, 60 mg, oral daily
Study: NCT01958957
Drug: Ginkgolides Meglumine Injection
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg, intravenous drip, once a day. Number of Cycles: 14 days.
Study: NCT00756548
Drug: polyethylene glycol 3350 based bowel preparation
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi-dose preparation for oral administration prior to colonoscopy
Study: NCT00486603
Drug: hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
Study: NCT00486603
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
Study: NCT01495481
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 2 mcg/kg, Intravenous push
Study: NCT04081805
Drug: Promestriene
Normalized name: promestriene
DrugBank: Promestriene (DB12487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
Study: NCT02126969
Drug: Docetaxel and Carboplatin AUC 6
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
Study: NCT00001839
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02367404
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 60mg OD for 3 months
Study: NCT00001839
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03696329
Drug: Tetrabenazine Tablets 25 mg
Normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00607048
Drug: Paclitaxel + Carboplatin + CP-870,893
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
Study: NCT00607048
Drug: Paclitaxel + Carboplatin + CP-870,893
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
Study: NCT00837187
Drug: Intravenous dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 ug
Study: NCT00837187
Drug: Intranasal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 ug
Study: NCT02194348
Drug: BIBN 4096 BS - in single rising doses
Normalized name: Rise Prot-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03594058
Drug: Solabegron modified release tablets, low dose
DrugBank: Solabegron (DB06190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Study: NCT03594058
Drug: Solabegron modified release tablets, high dose
DrugBank: Solabegron (DB06190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Study: NCT03881423
Drug: Rocuronium Bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DEEP block to PTC 1-3
Study: NCT03490760
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks
Study: NCT00930436
Drug: sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum creatinine will be measured on Days 3,7, 30, 90, and 180
Study: NCT00544284
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00544284
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00552760
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 8 mg tablet at bedtime for up to 6 months
Study: NCT01496911
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single oral dose of 5 mg
Study: NCT01496911
Drug: Hydroxyzine
Normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single oral dose of 50 mg
Study: NCT03783494
Drug: Target control infusion with propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
Study: NCT02645916
Drug: Placebo: corn starch
DrugBank: Corn (DB10572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT00369694
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
Study: NCT00369694
Drug: Terlipressin & then Dummy
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
Study: NCT00003558
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03327064
Drug: UAB30
Normalized name: 9CUAB30
DrugBank: 9CUAB30 (DB12316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
Study: NCT01009190
Drug: PF-01367338
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
Study: NCT01009190
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard doses of intravenous Carboplatin administered every 3 weeks
Study: NCT01009190
Drug: PF-01367338
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
Study: NCT00186277
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calculated per patient
Study: NCT00186277
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calculated per patient
Study: NCT00002447
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002447
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002447
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003558
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003558
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01157117
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.